Study summary
A blood test can show who will respond to a new anti-inflammatory antibody
26%in remission with tulisokibart, vs 1% with placebo
What was tested
Tulisokibart, an antibody blocking TL1A, a newer inflammatory target, against placebo, with a blood test used to predict who is likely to respond.
What they found
- Remission was 26% vs 1% in the main group.
- Among people whose blood test predicted a response, remission was 32% vs 11%.
What it means
The first UC drug trial built around a companion blood test. A phase 3 trial is now underway.
Last reviewed 2026-11-14 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.